论文部分内容阅读
目的:观察和评价DA蛳MA序贯疗法治疗急性髓细胞白血病(AML)M4、M5的疗效,并与以往常用的DA、HA、MA、EA等方案疗效作对比。方法:采用DNR 40 mg·m-2·d-1,连用3 d;Ara蛳C 70 mg·m-2·d-1~100 mg·m-2·d-1,连用5 d~7 d后即用MTZ 6 mg·m-2·d-1~8 mg·m-2·d-1,连用3 d;Ara蛳C 70 mg·m-2·d-1~100 mg·m-2·d-1,连用5 d~7 d。结果:治疗组CR率80.85 %,其中12例长期CR>12 个月,中位CR时间11个月,与对照组比较差异有显著性。而毒副反应不明显增加。结论:DA蛳MA序贯疗法是目前诱导治疗急性髓细胞白血病M4、M5较理想的方案之一。
OBJECTIVE: To observe and evaluate the efficacy of sequential therapy of DA 蛳 MA in the treatment of acute myeloid leukemia (M4) and M5 in patients with acute myeloid leukemia (AML), and to compare with the curative effects of conventional DA, HA, MA and EA. Methods: DNR 40 mg · m-2 · d-1 was used for 3 d and Ara cocculant 70 mg · m-2 · d-1 ~ 100 mg · m-2 · d-1 for 5 days to 7 days Then use MTZ 6 mg · m-2 · d-1 ~ 8 mg · m-2 · d-1 for 3 d, Ara 蛳 C 70 mg · m-2 · d-1 ~ 100 mg · m-2 · D-1, once every 5 d ~ 7 d. Results: The CR rate of the treatment group was 80.85%, of which 12 cases had long-term CR> 12 months and the median CR time was 11 months, which was significantly different from the control group. The toxic side effects did not significantly increase. Conclusions: The sequential therapy of DA 蛳 MA is one of the ideal solutions for the induction of acute myeloid leukemia M4 and M5.